Literature DB >> 15867256

Antiangiogenic properties of gold nanoparticles.

Priyabrata Mukherjee1, Resham Bhattacharya, Ping Wang, Ling Wang, Sujit Basu, Janice A Nagy, Anthony Atala, Debabrata Mukhopadhyay, Shay Soker.   

Abstract

Here, we report an intrinsic property of gold nanoparticles (nanogold): they can interact selectively with heparin-binding glycoproteins and inhibit their activity. Gold nanoparticles specifically bound vascular permeability factor/vascular endothelial growth factor (VPF/VEGF)-165 and basic fibroblast growth factor, two endothelial cell mitogens and mediators of angiogenesis resulting in inhibition of endothelial/fibroblast cell proliferation in vitro and VEGF-induced permeability as well as angiogenesis in vivo. In contrast, nanogold did not inhibit VEGF-121 or epidermal growth factor, two non-heparin-binding growth factors, mediated cell proliferation. Gold nanoparticles significantly inhibited VEGF receptor-2 phosphorylation, intracellular calcium release, and migration and RhoA activation in vitro. These results report for the first time a novel property of gold nanoparticles to bind heparin-binding proteins and thereby inhibit their subsequent signaling events.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15867256     DOI: 10.1158/1078-0432.CCR-04-2482

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  108 in total

Review 1.  Nanotherapeutic approaches for the treatment of rheumatoid arthritis.

Authors:  Christine T N Pham
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2011-08-11

2.  Preparation, physicochemical characterization and performance evaluation of gold nanoparticles in radiotherapy.

Authors:  Ali Kamiar; Reza Ghotalou; Hadi Vali Zadeh
Journal:  Adv Pharm Bull       Date:  2013-08-20

3.  Inhibitory effects of Semaphorin 3F as an alternative candidate to anti-VEGF monoclonal antibody on angiogenesis.

Authors:  Gamze Tan
Journal:  In Vitro Cell Dev Biol Anim       Date:  2019-08-16       Impact factor: 2.416

Review 4.  Enabling individualized therapy through nanotechnology.

Authors:  Jason H Sakamoto; Anne L van de Ven; Biana Godin; Elvin Blanco; Rita E Serda; Alessandro Grattoni; Arturas Ziemys; Ali Bouamrani; Tony Hu; Shivakumar I Ranganathan; Enrica De Rosa; Jonathan O Martinez; Christine A Smid; Rachel M Buchanan; Sei-Young Lee; Srimeenakshi Srinivasan; Matthew Landry; Anne Meyn; Ennio Tasciotti; Xuewu Liu; Paolo Decuzzi; Mauro Ferrari
Journal:  Pharmacol Res       Date:  2010-01-05       Impact factor: 7.658

Review 5.  [Use of nanoparticles in ophthalomology].

Authors:  I Hahn; P Heiduschka; E Endl; N Eter
Journal:  Ophthalmologe       Date:  2011-09       Impact factor: 1.059

Review 6.  Gold nanoparticles in cancer therapy.

Authors:  Zhao-Zhin Joanna Lim; Jia-En Jasmine Li; Cheng-Teng Ng; Lin-Yue Lanry Yung; Boon-Huat Bay
Journal:  Acta Pharmacol Sin       Date:  2011-07-11       Impact factor: 6.150

7.  Chemosensitization of cancer cells via gold nanoparticle-induced cell cycle regulation.

Authors:  Megan A Mackey; Mostafa A El-Sayed
Journal:  Photochem Photobiol       Date:  2014-02-11       Impact factor: 3.421

Review 8.  Targeted hyperthermia using metal nanoparticles.

Authors:  Paul Cherukuri; Evan S Glazer; Steven A Curley
Journal:  Adv Drug Deliv Rev       Date:  2009-11-10       Impact factor: 15.470

9.  Probing novel roles of the mitochondrial uniporter in ovarian cancer cells using nanoparticles.

Authors:  Rochelle R Arvizo; Daniel F Moyano; Sounik Saha; Michael A Thompson; Resham Bhattacharya; Vincent M Rotello; Y S Prakash; Priyabrata Mukherjee
Journal:  J Biol Chem       Date:  2013-04-24       Impact factor: 5.157

10.  Silver nanoparticles inhibit VEGF-and IL-1beta-induced vascular permeability via Src dependent pathway in porcine retinal endothelial cells.

Authors:  Sardarpasha Sheikpranbabu; Kalimuthu Kalishwaralal; Deepak Venkataraman; Soo Hyun Eom; Jongsun Park; Sangiliyandi Gurunathan
Journal:  J Nanobiotechnology       Date:  2009-10-30       Impact factor: 10.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.